Drug Distributor Shanghai Pharmaceuticals Plans New Share Offering In Hong Kong
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - China's second-largest drug distributor plans to issue shares in Hong Kong in less than a year as it builds up its acquisitions war chest
You may also be interested in...
All Eyes On China As Market Activity Heats Up
Mergers and acquisitions in China’s life sciences industry are ramping up, with some segments, such as the orthopedic device space, particularly hot. As Chinese companies rise with the market, alliance deals are increasing sharply and financing deals remain stable, according to EBI’s Strategic Transactions database.
Shanghai Pharmaceutical Expands North; NDRC Price Cuts Impact M&A Targets
SHANGHAI - To accelerate its expansion and strengthen its presence in North China, Shanghai Pharmaceutical Holding Co. in January opened a new representative office in Beijing and established Beijing Shanghai Pharma Aixin Weiye Pharmaceutical Co., to be known as Weiye Pharma, while at the same time announcing the planned acquisition of China Health System
Shanghai Pharmaceutical Expands North; NDRC Price Cuts Impact M&A Targets
SHANGHAI - To accelerate its expansion and strengthen its presence in North China, Shanghai Pharmaceutical Holding Co. in January opened a new representative office in Beijing and established Beijing Shanghai Pharma Aixin Weiye Pharmaceutical Co., to be known as Weiye Pharma, while at the same time announcing the planned acquisition of China Health System